Novo Nordisk A/S





Real-time Estimate Cboe Europe 07:38:45 2024-04-15 am EDT 5-day change 1st Jan Change
882.6 DKK +0.30% Intraday chart for Novo Nordisk A/S +1.15% +26.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biophytis: patent application filed in the field of obesity CF
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup DJ
European Equities Close Mixed in Friday Trading; German Inflation Slows, UK GDP Rises MT
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says DJ
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says MT
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says MT
European Medicines Agency Finds No Increased Suicide Risk Link to Novo Nordisk's Wegovy, Ozempic MT
BMO Capital Starts Novo Nordisk With Outperform Rating, $163 Price Target MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts RE
Gerresheimer shares down on outlook, but key contracts confirmed RE
Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says RE
Gerresheimer expects sales boost from burgeoning obesity drugs sector RE
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update DJ
Ginkgo Bioworks Expands Research Partnership With Novo Nordisk MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Biophytis launches clinical study in obesity CF
Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal MT
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Softer Monday Afternoon MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday MT
Novo Nordisk Parent Resubmits US Antirust Application for Catalent Acquisition MT
Novo Nordisk parent refiles US application on Catalent deal RE
Novo Nordisk owner refiles U.S. application for approval of Catalent deal RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
880 DKK
Average target price
904.2 DKK
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Vivani Medical Shares Soar on Positive NPM-115 Preclinical Weight Loss Data